GlassScriptPhysician profile
Heather E Pontasch
NPI 1114242674
$3,473.25
in general payments reported to CMS, 2019-2025
30 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $99.09 · 2021: $263 · 2022: $616 · 2023: $1,124 · 2024: $704 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.56 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.07 | 2020-2025 | |
| Genzyme Corporation | $388.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $341.63 | 2019-2025 | |
| Leo Pharma INC. | $250.87 | 2020-2024 | Adbry |
| Lilly USA, LLC | $198.17 | 2021-2024 | Taltz, Olumiant |
| Merz North America, INC. | $196.72 | 2023 | Xeomin |
| Pfizer INC. | $162.28 | 2022-2025 | |
| Amgen INC. | $155.79 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $149.54 | 2020-2025 | Oracea, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $114.08 | 2021-2024 | Ilumya |
| Janssen Biotech, INC. | $106.15 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $98.62 | 2019-2025 | Dupixent |
| Ucb, INC. | $69.91 | 2021-2023 | Bimzelx |
| Incyte Corporation | $68.11 | 2022-2024 | Opzelura |
| Merck Sharp & Dohme LLC | $67.03 | 2023-2024 | Keytruda |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $62.39 | 2023-2024 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $44.99 | 2023-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $42.15 | 2023 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $33.75 | 2022-2023 | Sotyktu |
| Organogenesis INC. | $29.37 | 2023 | Puraply |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.43 | 2025 | Jublia, Cabtreo |
| Dermavant Sciences, INC. | $23.68 | 2023 | Vtama |
| Dermira, INC. | $20.77 | 2021 | |
| Smith+Nephew, INC. | $19.32 | 2024 | Collagenase Santyl |
| Mayne Pharma Commercial LLC | $18.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2023 | Spevigo |
| Kerecis Limited | $18.74 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Celgene Corporation | $17.08 | 2019 | |
| Vyne Pharmaceuticals INC. | $16.76 | 2021 | |
| Almirall LLC | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Pontasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.